Partnership Brings New Imaging Technology to the Preclinical Market

The partnership would unite Philips' strength in medical imaging and Bruker BioSpin's leadership in analytic magnetic resonance instruments and preclinical magnetic resonance imaging (MRI). Under the terms of the MOU, Bruker BioSpin intends to develop and manufacture the preclinical MPI scanner at its facilities in Ettlingen, Germany. Both parties intend to jointly market the resulting system. Preclinical imaging has emerged as a powerful tool in disease studies, translational research, and drug discovery. Philips and Bruker BioSpin believe that the addition of MPI as a complementary preclinical imaging technique has great potential to help researchers gain new insights in disease processes at the organ, cellular, and molecular level.

MPI is a new medical imaging technology developed by scientists at Philips. It uses the magnetic properties of iron-oxide nanoparticles to produce three-dimensional (3D) images of the concentration of nanoparticles injected into the bloodstream. The potential of the technology for medical and industrial research and, ultimately, patient care, was demonstrated in a publication, which appeared in the March 2009 issue of the journal Physics in Medicine and Biology. It was demonstrated that MPI technology could be used to produce real-time images that accurately capture the activity in the cardiovascular system of a mouse.

"We are very pleased about this collaboration with Philips on this exciting technology. Magnetic particle imaging is expected to allow scientists to explore an extensive range of new imaging capabilities and applications in preclinical research,” said Wulf-Ingo Jung, managing director of Bruker BioSpin MRI, GmbH. "The highly sensitive visualization of functional characteristics in vivo at high temporal resolution bears great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI.”

"Through its combined speed, resolution, and sensitivity, our magnetic particle imaging technology has great potential for the diagnosis, therapy planning, and therapy response assessment for major diseases, such as heart disease and cancer,” said Diego Olego, senior vice president and chief technology officer of Philips Healthcare. "We are excited about the agreement with Bruker BioSpin as it will lead to the availability of MPI scanners for preclinical research studies, which is a prerequisite for establishing the value of this promising new technology for patient care.”

A major success factor for the effective translation of new imaging concepts into practice is establishing partnerships with leading academic medical institutions, industrial partners, and governments The results obtained in the Magnetic Particle Imaging for Cardio-Vascular Applications (MAGIC) research project conducted at the Philips Research Laboratories in Hamburg, Germany, have significantly contributed to the development of MPI. The project was started in 2006 and will finish by the end of 2009.

Related Links:
Philips Healthcare
Bruker BioSpin